2016 VAM: 2809 - Novel Biologicals for Asthma and Allergic Rhinosinusitis

This session will aim to inform about two major therapeutic strategies, namely biologicals and allergen-speciffic immunothrapy for asthma and allergic rhinits and their mechanisms of action.  Allergen-specific immunotherapy, aims to induce specific immune tolerance and has a long-term disease-modifying effect.  The second approach is the use of biological immune response modifiers to decrease pathological immune responses targeting a dominant inflammatory mechanism, such as IgE, IL-5, IL-13.

AMA PRA Category 1 Credits™: 1.25
CE: 1.25

Credit must be claimed by May 31, 2018.  Any credit request on or after June 1, 2018 will be subject to an administrative fee.

Target Audience

Physicians
Allergists/Immunologists
Nurses
Nurse Practitioners
Allied Health Professionals

Learning Objectives

Upon completion of this activity, participants will be able to:
1.  Discuss novel biologicals in allergy and immunology
2.  Discuss mechanisms underlying novel immunologic therapies

Additional Information

AttachmentSize
2016 Annual Meeting Disclosures120.13 KB
Summary
Available credit: 
  • 1.25 Attendance
    Attendance credit.
  • 1.25 CE
    CE credit.
  • 1.25 CME
    CME credit.
Course opens: 
05/31/2016
Course expires: 
05/31/2018
Cost:
$15.00
Rating: 
0

Prof. Cezmi A. Akdis, MD FAAAAI, Swiss Institute of Allergy and Asthma Research, Davos, Switzerland

Prof. Claus Bachert, MD PhD, Upper Airway Research Laboratory (URL), Ghent University Hospital, Ghent, Belgium

Dr. Sally E. Wenzel, MD FAAAAI, University of Pittsburgh Medical Center NW, Pittsburgh, PA

Available Credit

  • 1.25 Attendance
    Attendance credit.
  • 1.25 CE
    CE credit.
  • 1.25 CME
    CME credit.

Accreditation Period

Course opens: 
05/31/2016
Course expires: 
05/31/2018

Price

Cost:
$15.00
Please login or register to take this course.

Required Hardware/software

Our system supports the two most recent versions of Safari, Google Chrome, and Firefox. Internet Explorer is not recommended.